Abstract
Alzheimer’s disease (AD) is a common neurodegenerative disease characterized by amyloid plaque and neurofibrillary tangles (NFT). With the finding that soluble nonfibrillar Aβ levels actually correlate strongly with the severity of the disease, the initial focus on amyloid plaques shifted to the contemporary concept that AD memory failure is caused by soluble Aβ oligomers. The soluble Aβ are known to be more neurotoxicthan fibrillar Aβ species. In this paper, we summarize the essential role of soluble Aβ oligomers in AD and discuss therapeutic strategies that target soluble Aβ oligomers.
Similar content being viewed by others
References
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6):860–866
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155(3):853–862
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572–580. doi:10.1002/ana.410300410
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16(3):285–298, discussion 298-304
Wilcox KC, Lacor PN, Pitt J, Klein WL (2011) Abeta oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol 31(6):939–948. doi:10.1007/s10571-011-9691-4
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100(18):10417–10422. doi:10.1073/pnas.1834302100
Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283(44):29639–29643. doi:10.1074/jbc.R800016200
Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282(4):2646–2655. doi:10.1074/jbc.M606202200
Yanagisawa K (2007) Role of gangliosides in Alzheimer’s disease. Biochim Biophys Acta 1768(8):1943–1951. doi:10.1016/j.bbamem.2007.01.018
Yuyama K, Yamamoto N, Yanagisawa K (2008) Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. J Neurochem 105(1):217–224. doi:10.1111/j.1471-4159.2007.05128.x
Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A, Boelens WC, Bosman GJ, de Jong WW (1999) The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun 262(1):152–156. doi:10.1006/bbrc.1999.1167
Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF et al (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136(1):22–31
Sakono M, Zako T, Ueda H, Yohda M, Maeda M (2008) Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. FEBS J 275(23):5982–5993. doi:10.1111/j.1742-4658.2008.06727.x
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. doi:10.1126/science.1072994
Mucke HA (2000) Apoptosis modulators: targeting cellular suicide. IDrugs 3(5):506–511
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 5(5):452–457. doi:10.1038/nn842
Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE (1994) Purification and characterization of brain clusterin. Biochem Biophys Res Commun 204(3):1131–1136. doi:10.1006/bbrc.1994.2580
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81(2):741–766
Cruz L, Urbanc B, Buldyrev SV, Christie R, Gomez-Isla T, Havlin S, McNamara M, Stanley HE, Hyman BT (1997) Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci U S A 94(14):7612–7616
Hyman BT, Marzloff K, Arriagada PV (1993) The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 52(6):594–600
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106(10):4012–4017. doi:10.1073/pnas.0811698106
Serrano-Pozo A, Mielke ML, Muzitansky A, Gomez-Isla T, Growdon JH, Bacskai BJ, Betensky RA, Frosch MP, Hyman BT (2012) Stable size distribution of amyloid plaques over the course of Alzheimer disease. J Neuropathol Exp Neurol 71(8):694–701. doi:10.1097/NEN.0b013e31825e77de
Oide T, Kinoshita T, Arima K (2006) Regression stage senile plaques in the natural course of Alzheimer's disease. Neuropathol Appl Neurobiol 32(5):539–556. doi:10.1111/j.1365-2990.2006.00767.x
Liao D, Miller EC, Teravskis PJ (2014) Tau acts as a mediator for Alzheimer’s disease-related synaptic deficits. Eur J Neurosci 39(7):1202–1213. doi:10.1111/ejn.12504
Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH (2013) Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol 70(5):594–599. doi:10.1001/jamaneurol.2013.48
Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid-beta oligomers in ageing and Alzheimer’s disease. Brain 136(Pt 5):1383–1398. doi:10.1093/brain/awt062
Zussy C, Brureau A, Keller E, Marchal S, Blayo C, Delair B, Ixart G, Maurice T, Givalois L (2013) Alzheimer’s disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-beta peptide injection in rats. PLoS One 8(1):e53117. doi:10.1371/journal.pone.0053117
Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci Off J Soc Neurosci 30(36):11938–11950. doi:10.1523/JNEUROSCI. 2357-10.2010
Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68(6):1067–1081. doi:10.1016/j.neuron.2010.11.030
Miller EC, Teravskis PJ, Dummer BW, Zhao X, Huganir RL, Liao D (2014) Tau phosphorylation and tau mislocalization mediate soluble Abeta oligomer-induced AMPA glutamate receptor signaling deficits. Eur J Neurosci 39(7):1214–1224. doi:10.1111/ejn.12507
Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Buee L (2012) Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci Off J Soc Neurosci 32(23):7852–7861. doi:10.1523/JNEUROSCI. 5901-11.2012
Tokutake T, Kasuga K, Yajima R, Sekine Y, Tezuka T, Nishizawa M, Ikeuchi T (2012) Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J Biol Chem 287(42):35222–35233. doi:10.1074/jbc.M112.348300
Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM (2012) Soluble abeta promotes wild-type tau pathology in vivo. J Neurosci Off J Soc Neurosci 32(48):17345–17350. doi:10.1523/JNEUROSCI. 0172-12.2012
Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, Morgan D (2013) Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis 11(4):165–181. doi:10.1159/000337230
Guo JP, Arai T, Miklossy J, McGeer PL (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease. Proc Natl Acad Sci U S A 103(6):1953–1958. doi:10.1073/pnas.0509386103
Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B, Cowburn RF (2003) Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J Neurochem 87(5):1152–1164
Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, Roberson ED, Bloom GS (2013) Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer’s disease. J Cell Sci 126(Pt 5):1278–1286. doi:10.1242/jcs.1125880
Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R, Lu B (2012) A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet 21(6):1384–1390. doi:10.1093/hmg/ddr576
Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120(Suppl 1):125–139. doi:10.1111/j.1471-4159.2011.07478.x
Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE (2012) The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 32(47):16857–16871
Cullen WK, Suh YH, Anwyl R, Rowan MJ (1997) Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8(15):3213–3217
Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ (2001) Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci Off J Soc Neurosci 21(4):1327–1333
Lynch MA (2004) Long-term potentiation and memory. Physiol Rev 84(1):87–136. doi:10.1152/physrev.00014.2003
Neves G, Cooke SF, Bliss TV (2008) Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci 9(1):65–75. doi:10.1038/nrn2303
Collingridge GL, Peineau S, Howland JG, Wang YT (2010) Long-term depression in the CNS. Nat Rev Neurosci 11(7):459–473. doi:10.1038/nrn2867
Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, Waeg G, Mattson MP (1997) 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 80(3):685–696
Blanc EM, Keller JN, Fernandez S, Mattson MP (1998) 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia 22(2):149–160
Mark RJ, Hensley K, Butterfield DA, Mattson MP (1995) Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosc Off J Soc Neurosci 15(9):6239–6249
Shi C, Wu F, Xu J (2010) H2O2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761. Neurochem Int 56(8):893–905. doi:10.1016/j.neuint.2010.03.016
Ikegaya Y, Matsuura S, Ueno S, Baba A, Yamada MK, Nishiyama N, Matsuki N (2002) Beta-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J Biol Chem 277(35):32180–32186. doi:10.1074/jbc.M203764200
Fernandez-Tome P, Brera B, Arevalo MA, de Ceballos ML (2004) Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism. Neurobiol Dis 15(3):580–589. doi:10.1016/j.nbd.2003.12.006
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14(8):837–842. doi:10.1038/nm1782
Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60(6):982–990. doi:10.1016/j.neuropharm.2011.01.051
Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM (2007) Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci Off J Soc Neurosci 27(29):7648–7653. doi:10.1523/JNEUROSCI. 0395-07.2007
Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7(6):824–835. doi:10.1111/j.1474-9726.2008.00434.x
Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci Off J Soc Neurosci 24(13):3370–3378. doi:10.1523/JNEUROSCI. 1633-03.2004
Chen L, Wang H, Zhang Z, Li Z, He D, Sokabe M, Chen L (2010) DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor. J Neurosci Res 88(8):1784–1794. doi:10.1002/jnr.22345
Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ (2013) Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 341(6152):1399–1404. doi:10.1126/science.1242077
Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S (2009) Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry 14(2):206–222. doi:10.1038/mp.2008.105
Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci Off J Soc Neurosci 31(18):6627–6638. doi:10.1523/JNEUROSCI. 0203-11.2011
Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci Off J Soc Neurosci 28(53):14537–14545. doi:10.1523/JNEUROSCI. 2692-08.2008
Kullmann DM, Lamsa KP (2007) Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci 8(9):687–699. doi:10.1038/nrn2207
Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62(6):788–801. doi:10.1016/j.neuron.2009.05.012
Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304(5673):1021–1024. doi:10.1126/science.1096615
Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15(3):349–357. doi:10.1038/nn.3028
Gu Z, Liu W, Yan Z (2009) {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem 284(16):10639–10649. doi:10.1074/jbc.M806508200
Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci Off J Soc Neurosci 25(48):11061–11070. doi:10.1523/JNEUROSCI. 3034-05.2005
Rui Y, Gu J, Yu K, Hartzell HC, Zheng JQ (2010) Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: the mitochondrial contribution. Mol Brain 3:10. doi:10.1186/1756-6606-3-10
Minano-Molina AJ, Espana J, Martin E, Barneda-Zahonero B, Fado R, Sole M, Trullas R, Saura CA, Rodriguez-Alvarez J (2011) Soluble oligomers of amyloid-beta peptide disrupt membrane trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. J Biol Chem 286(31):27311–27321. doi:10.1074/jbc.M111.227504
Barria A, Derkach V, Soderling T (1997) Identification of the Ca2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor. J Biol Chem 272(52):32727–32730
Ouyang Y, Wong M, Capani F, Rensing N, Lee CS, Liu Q, Neusch C, Martone ME, Wu JY, Yamada K, Ellisman MH, Choi DW (2005) Transient decrease in F-actin may be necessary for translocation of proteins into dendritic spines. Eur J Neurosci 22(12):2995–3005. doi:10.1111/j.1460-9568.2005.04521.x
Decker H, Jurgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST (2010) N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid-beta peptide oligomers. J Neurochem 115(6):1520–1529. doi:10.1111/j.1471-4159.2010.07058.x
Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8(8):1051–1058. doi:10.1038/nn1503
Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG (2011) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 32(12):2219–2228. doi:10.1016/j.neurobiolaging.2010.01.011
Dinamarca MC, Colombres M, Cerpa W, Bonansco C, Inestrosa NC (2008) Beta-amyloid oligomers affect the structure and function of the postsynaptic region: role of the Wnt signaling pathway. Neurodegener Dis 5(3–4):149–152. doi:10.1159/000113687
Kelly BL, Ferreira A (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281(38):28079–28089. doi:10.1074/jbc.M605081200
Texido L, Martin-Satue M, Alberdi E, Solsona C, Matute C (2011) Amyloid beta peptide oligomers directly activate NMDA receptors. Cell Calcium 49(3):184–190. doi:10.1016/j.ceca.2011.02.001
Paula-Lima AC, Brito-Moreira J, Ferreira ST (2013) Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer’s disease. J Neurochem 126(2):191–202. doi:10.1111/jnc.12304
Lauren J (2014) Cellular prion protein as a therapeutic target in Alzheimer’s disease. J Alzheimers Dis 38(2):227–244. doi:10.3233/JAD-130950
Chen S, Yadav SP, Surewicz WK (2010) Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 285(34):26377–26383. doi:10.1074/jbc.M110.145516
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457(7233):1128–1132. doi:10.1038/nature07761
Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2:336. doi:10.1038/ncomms1341
Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ (2011) Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci Off J Soc Neurosci 31(20):7259–7263. doi:10.1523/JNEUROSCI. 6500-10.2011
Bate C, Williams A (2011) Amyloid-beta-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem 286(44):37955–37963. doi:10.1074/jbc.M111.248724
Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G, Borsello T, Gobbi M, Harris DA (2013) An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 288(11):7857–7866. doi:10.1074/jbc.M112.423954
Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FU, Multhaup G, Winklhofer KF, Tatzelt J (2011) The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J 30(10):2057–2070. doi:10.1038/emboj.2011.86
Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15(9):1227–1235. doi:10.1038/nn.3178
You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, Engbers JD, Lipton SA, Stys PK, Zamponi GW (2012) Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 109(5):1737–1742. doi:10.1073/pnas.1110789109
Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79(5):887–902. doi:10.1016/j.neuron.2013.06.036
Biasini E, Unterberger U, Solomon IH, Massignan T, Senatore A, Bian H, Voigtlaender T, Bowman FP, Bonetto V, Chiesa R, Luebke J, Toselli P, Harris DA (2013) A mutant prion protein sensitizes neurons to glutamate-induced excitotoxicity. J Neurosci Off J Soc Neurosci 33(6):2408–2418. doi:10.1523/JNEUROSCI. 3406-12.2013
Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G (2010) Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 107(5):2295–2300. doi:10.1073/pnas.0911829107
Niedowicz DM, Beckett TL, Matveev S, Weidner AM, Baig I, Kryscio RJ, Mendiondo MS, LeVine H 3rd, Keller JN, Murphy MP (2012) Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol 72(4):564–570. doi:10.1002/ana.23633
Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298(5594):789–791. doi:10.1126/science.1074069
Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS (2001) Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc Natl Acad Sci U S A 98(25):14675–14680. doi:10.1073/pnas.261562998
Chen Z, Zhong C (2014) Oxidative stress in Alzheimer’s disease. Neurosci Bull 30(2):271–281. doi:10.1007/s12264-013-1423-y
Bondy SC, Guo-Ross SX, Truong AT (1998) Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res 799(1):91–96
Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32(11):1050–1060
Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H 3rd, Lott IT, Schmitt FA, Butterfield DA, Head E (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822(2):130–138. doi:10.1016/j.bbadis.2011.10.001
Hodgson N, Trivedi M, Muratore C, Li S, Deth R (2013) Soluble oligomers of amyloid-beta cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. J Alzheimers Dis 36(1):197–209. doi:10.3233/JAD-130101
Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, Hatsuta H, Murayama S, Barnham KJ, Irie K, Shirasawa T, Shimizu T (2011) SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 286(52):44557–44568. doi:10.1074/jbc.M111.279208
Murakami K, Murata N, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T (2011) Vitamin C restores behavioral deficits and amyloid-beta oligomerization without affecting plaque formation in a mouse model of Alzheimer’s disease. J Alzheimers Dis 26(1):7–18. doi:10.3233/JAD-2011-101971
Cimini A, Gentile R, D’Angelo B, Benedetti E, Cristiano L, Avantaggiati ML, Giordano A, Ferri C, Desideri G (2013) Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer's disease model by modulating BDNF signaling pathway. J Cell Biochem 114(10):2209–2220. doi:10.1002/jcb.24548
Xu PX, Wang SW, Yu XL, Su YJ, Wang T, Zhou WW, Zhang H, Wang YJ, Liu RT (2014) Rutin improves spatial memory in Alzheimer’s disease transgenic mice by reducing Abeta oligomer level and attenuating oxidative stress and neuroinflammation. Behav Brain Res 264:173–180. doi:10.1016/j.bbr.2014.02.002
Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 91(8):3270–3274
Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin L, Bummer P, Wang Y, Pedigo NW Jr, Butterfield DA (1995) beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer’s disease. Neuroreport 6(14):1875–1879
Manelli AM, Puttfarcken PS (1995) beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res Bull 38(6):569–576
Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H (1995) Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 92(6):1989–1993
Ii M, Sunamoto M, Ohnishi K, Ichimori Y (1996) beta-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res 720(1–2):93–100. doi:10.1016/0006-8993(96)00156-4
Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48(1):136–144. doi:10.1016/j.freeradbiomed.2009.10.035
Greenough MA, Camakaris J, Bush AI (2013) Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62(5):540–555. doi:10.1016/j.neuint.2012.08.014
Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275(26):19439–19442. doi:10.1074/jbc.C000165200
Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15(9):1437–1449. doi:10.1093/hmg/ddl066
Rhein V, Baysang G, Rao S, Meier F, Bonert A, Muller-Spahn F, Eckert A (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29(6–7):1063–1071. doi:10.1007/s10571-009-9398-y
Young KJ, Bennett JP (2010) The mitochondrial secret(ase) of Alzheimer’s disease. J Alzheimers Dis 20(Suppl 2):S381–S400. doi:10.3233/JAD-2010-100360
Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57:683–706. doi:10.1146/annurev.ph.57.030195.003343
Quiroz-Baez R, Flores-Dominguez D, Arias C (2013) Synaptic aging is associated with mitochondrial dysfunction, reduced antioxidant contents and increased vulnerability to amyloid-beta toxicity. CurrAlzheimer Res 10(3):324–331
Town T, Nikolic V, Tan J (2005) The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2:24. doi:10.1186/1742-2094-2-24
Paranjape GS, Gouwens LK, Osborn DC, Nichols MR (2012) Isolated amyloid-beta(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. ACS Chem Neurosci 3(4):302–311. doi:10.1021/cn2001238
Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87(3):181–194
Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer’s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci Off J Soc Neurosci 28(45):11650–11661. doi:10.1523/JNEUROSCI. 3024-08.2008
Dewapriya P, Li YX, Himaya SW, Pangestuti R, Kim SK (2013) Neoechinulin A suppresses amyloid-beta oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity. Neurotoxicology 35:30–40. doi:10.1016/j.neuro.2012.12.004
He Y, Zheng MM, Ma Y, Han XJ, Ma XQ, Qu CQ, Du YF (2012) Soluble oligomers and fibrillar species of amyloid beta-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem Biophys Res Commun 429(3–4):125–130. doi:10.1016/j.bbrc.2012.10.129
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21(3):383–421
DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, Sereno L, Rodriguez M, Sanchez B, Hyman BT, Gomez-Isla T (2011) Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70(5):360–376. doi:10.1097/NEN.0b013e318217a118
White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ (2005) Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18(3):459–465. doi:10.1016/j.nbd.2004.12.013
Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 43(1):1–16
Rossner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR (2005) Alzheimer’s disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92(2):226–234. doi:10.1111/j.1471-4159.2004.02857.x
Choi DY, Lee YJ, Hong JT, Lee HJ (2012) Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 87(2–3):144–153. doi:10.1016/j.brainresbull.2011.11.014
Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558):408–414
Contestabile A (2011) The history of the cholinergic hypothesis. Behav Brain Res 221(2):334–340. doi:10.1016/j.bbr.2009.12.044
Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2):555–563. doi:10.1016/j.bbr.2010.11.058
Nunes-Tavares N, Santos LE, Stutz B, Brito-Moreira J, Klein WL, Ferreira ST, de Mello FG (2012) Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-beta peptide oligomers. J Biol Chem 287(23):19377–19385. doi:10.1074/jbc.M111.321448
Wang HY, Lee DH, Davis CB, Shank RP (2000) Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75(3):1155–1161
Liu Q, Kawai H, Berg DK (2001) beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 98(8):4734–4739. doi:10.1073/pnas.081553598
Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection. Pharmacol Rev 61(1):39–61. doi:10.1124/pr.108.000562
Nagele RG, D’Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110(2):199–211
Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s disease. J Neurosci Off J Soc Neurosci 21(12):4125–4133
Fodero LR, Mok SS, Losic D, Martin LL, Aguilar MI, Barrow CJ, Livett BG, Small DH (2004) Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 88(5):1186–1193
Dineley KT, Bell KA, Bui D, Sweatt JD (2002) beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277(28):25056–25061. doi:10.1074/jbc.M200066200
Lee DH, Wang HY (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55(1):25–30. doi:10.1002/neu.10203
Pettit DL, Shao Z, Yakel JL (2001) beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci Off J Soc Neurosci 21(1):RC120
Tozaki H, Matsumoto A, Kanno T, Nagai K, Nagata T, Yamamoto S, Nishizaki T (2002) The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Biochem Biophys Res Commun 294(1):42–45. doi:10.1016/S0006-291X(02)00429-1
Chin JH, Ma L, MacTavish D, Jhamandas JH (2007) Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J Neurosci Off J Soc Neurosci 27(35):9262–9269. doi:10.1523/JNEUROSCI. 1843-07.2007
Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci Off J Soc Neurosci 29(4):918–929. doi:10.1523/JNEUROSCI. 3952-08.2009
Li JQ, Yu JT, Jiang T, Tan L (2014) Endoplasmic reticulum dysfunction in Alzheimer’s disease. Mol Neurobiol. doi:10.1007/s12035-014-8695-8
Resende R, Ferreiro E, Pereira C, Oliveira CR (2008) ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J Neurosci Res 86(9):2091–2099. doi:10.1002/jnr.21648
Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 31(9):454–463. doi:10.1016/j.tins.2008.06.005
Green KN, LaFerla FM (2008) Linking calcium to Abeta and Alzheimer’s disease. Neuron 59(2):190–194. doi:10.1016/j.neuron.2008.07.013
Berridge MJ (2011) Calcium signalling and Alzheimer’s disease. Neurochem Res 36(7):1149–1156. doi:10.1007/s11064-010-0371-4
Demuro A, Parker I, Stutzmann GE (2010) Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 285(17):12463–12468. doi:10.1074/jbc.R109.080895
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618):486–489. doi:10.1126/science.1079469
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416(6880):507–511. doi:10.1038/416507a
Simakova O, Arispe NJ (2006) Early and late cytotoxic effects of external application of the Alzheimer’s Abeta result from the initial formation and function of Abeta ion channels. Biochemistry 45(18):5907–5915. doi:10.1021/bi060148g
Demuro A, Smith M, Parker I (2011) Single-channel Ca(2+) imaging implicates Abeta1-42 amyloid pores in Alzheimer’s disease pathology. J Cell Biol 195(3):515–524. doi:10.1083/jcb.201104133
Resende R, Ferreiro E, Pereira C, Resende de Oliveira C (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155(3):725–737. doi:10.1016/j.neuroscience.2008.06.036
Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89(7):1031–1042. doi:10.1002/jnr.22640
Jensen LE, Bultynck G, Luyten T, Amijee H, Bootman MD, Roderick HL (2013) Alzheimer's disease-associated peptide Abeta42 mobilizes ER Ca(2+) via InsP3R-dependent and -independent mechanisms. Front Mol Neurosci 6:36. doi:10.3389/fnmol.2013.00036
Lee S, Zemianek J, Shea TB (2013) Rapid, reversible impairment of synaptic signaling in cultured cortical neurons by exogenously-applied amyloid-beta. J Alzheimers Dis 35(2):395–402. doi:10.3233/JAD-122452
Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63(10):1902–1907
Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474–481
Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490(1–3):169–175. doi:10.1016/j.ejphar.2004.02.054
Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 48(12):2460–2469. doi:10.1007/s00125-005-0023-4
Craft S (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20(4):298–301. doi:10.1097/01.wad.0000213866.86934.7e
Hoyer S (2003) Memory function and brain glucose metabolism. Pharmacopsychiatry 36(Suppl 1):S62–S67. doi:10.1055/s-2003-40452
de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 7(1):45–61
Kenyon CJ (2010) The genetics of ageing. Nature 464(7288):504–512. doi:10.1038/nature08980
Panowski SH, Dillin A (2009) Signals of youth: endocrine regulation of aging in Caenorhabditis elegans. Trends Endocrinol Metab 20(6):259–264. doi:10.1016/j.tem.2009.03.006
Douglas PM, Dillin A (2010) Protein homeostasis and aging in neurodegeneration. J Cell Biol 190(5):719–729. doi:10.1083/jcb.201005144
Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282(46):33305–33312. doi:10.1074/jbc.M610390200
Han X, Ma Y, Liu X, Wang L, Qi S, Zhang Q, Du Y (2012) Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer’s disease rat model. J Neural Transm 119(11):1407–1416. doi:10.1007/s00702-012-0803-1
De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106(6):1971–1976. doi:10.1073/pnas.0809158106
Franke TF (2008) PI3K/Akt: getting it right matters. Oncogene 27(50):6473–6488. doi:10.1038/onc.2008.313
Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 93(1):105–117. doi:10.1111/j.1471-4159.2004.02949.x
Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1):246–260. doi:10.1096/fj.06-7703com
Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT (2009) The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener 4:14. doi:10.1186/1750-1326-4-14
Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magri A, Oddo S (2011) Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 286(11):8924–8932. doi:10.1074/jbc.M110.180638
Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 285(17):13107–13120. doi:10.1074/jbc.M110.100420
Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging cell 11(2):326–335. doi:10.1111/j.1474-9726.2011.00791.x
Heras-Sandoval D, Ferrera P, Arias C (2012) Amyloid-beta protein modulates insulin signaling in presynaptic terminals. Neurochem Res 37(9):1879–1885. doi:10.1007/s11064-012-0800-7
Kwak YD, Ma T, Diao S, Zhang X, Chen Y, Hsu J, Lipton SA, Masliah E, Xu H, Liao FF (2010) NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol Neurodegener 5:49. doi:10.1186/1750-1326-5-49
Bartl J, Meyer A, Brendler S, Riederer P, Grunblatt E (2013) Different effects of soluble and aggregated amyloid beta42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm 120(1):113–120. doi:10.1007/s00702-012-0852-5
Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, Carmona-Cuenca I, Caballero C, Ruano D, Gutierrez A, Vitorica J (2011) Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 286(21):18414–18425. doi:10.1074/jbc.M110.209718
Ehninger D, de Vries PJ, Silva AJ (2009) From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 53(10):838–851. doi:10.1111/j.1365-2788.2009.01208.x
Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53(5):703–717. doi:10.1016/j.neuron.2007.01.029
Hou L, Klann E (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci Off J Soc Neurosci 24(28):6352–6361. doi:10.1523/JNEUROSCI. 0995-04.2004
Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33(2):67–75. doi:10.1016/j.tins.2009.11.003
Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, LaDu M, Busciglio J, Brady S (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A 106(14):5907–5912. doi:10.1073/pnas.0901229106
Decker H, Lo KY, Unger SM, Ferreira ST, Silverman MA (2010) Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci Off J Soc Neurosci 30(27):9166–9171. doi:10.1523/JNEUROSCI. 1074-10.2010
Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21(3):281–293. doi:10.1093/emboj/21.3.281
Tang Y, Scott DA, Das U, Edland SD, Radomski K, Koo EH, Roy S (2012) Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid beta-protein oligomers. Traffic 13(5):681–693. doi:10.1111/j.1600-0854.2012.01340.x
Wang ZX, Tan L, Yu JT (2014) Axonal transport defects in Alzheimer’s disease. Mol Neurobiol. doi:10.1007/s12035-014-8810-x
Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Capurso A, et al (2009) Disease-modifying approach to the treatment of Alzheimer’s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26(7):537–555. doi:10.2165/11315770-000000000-00000
Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A (2011) Therapeutic intervention for Alzheimer’s disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 20(3):325–341. doi:10.1517/13543784.2011.550572
Ono K, Yamada M (2011) Low-n oligomers as therapeutic targets of Alzheimer’s disease. J Neurochem 117(1):19–28. doi:10.1111/j.1471-4159.2011.07187.x
Belluti F, Rampa A, Gobbi S, Bisi A (2013) Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimer’s disease: a patent review (2010–2012). Expert Opin Ther Patents 23(5):581–596. doi:10.1517/13543776.2013.772983
Zhang Y, Zhen Y, Dong Y, Xu Z, Yue Y, Golde TE, Tanzi RE, Moir RD, Xie Z (2011) Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Abeta oligomerization. PLoS One 6(11):e27019. doi:10.1371/journal.pone.0027019
O'Hare E, Scopes DI, Kim EM, Palmer P, Jones M, Whyment AD, Spanswick D, Amijee H, Nerou E, McMahon B, Treherne JM, Jeggo R (2013) Orally bioavailable small molecule drug protects memory in Alzheimer’s disease models. Neurobiol Aging 34(4):1116–1125. doi:10.1016/j.neurobiolaging.2012.10.016
Parachikova A, Green KN, Hendrix C, LaFerla FM (2010) Formulation of a medical food cocktail for Alzheimer’s disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One 5(11):e14015. doi:10.1371/journal.pone.0014015
Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7(3):369–372. doi:10.1038/85525
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916–919. doi:10.1038/78682
Wisniewski T, Konietzko U (2008) Amyloid-beta immunisation for Alzheimer’s disease. Lancet Neurol 7(9):805–811. doi:10.1016/S1474-4422(08)70170-4
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A (2012) Immunotherapy for Alzheimer’s disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 4(2):213–238. doi:10.2217/imt.11.170
Wisniewski T, Goni F (2014) Immunotherapy for Alzheimer’s disease. Biochem Pharmacol 88(4):499–507. doi:10.1016/j.bcp.2013.12.020
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98(15):8850–8855. doi:10.1073/pnas.151261398
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, Team ANS (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9):1553–1562. doi:10.1212/01.WNL.0000159740.16984.3C
Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11):1040–1048. doi:10.1097/01.jnen.0000240466.10758.ce
Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y (2012) Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease? J Neurosci Res 90(6):1105–1118. doi:10.1002/jnr.23011
Sandoval KE, Farr SA, Banks WA, Crider AM, Morley JE, Witt KA (2013) Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Abeta(42) oligomers via a metalloproteinase-dependent mechanism. Brain Res 1520:145–156. doi:10.1016/j.brainres.2013.05.006
Logan SM, Sarkar SN, Zhang Z, Simpkins JW (2011) Estrogen-induced signaling attenuates soluble Abeta peptide-mediated dysfunction of pathways in synaptic plasticity. Brain Res 1383:1–12. doi:10.1016/j.brainres.2011.01.038
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (81471309, 81371406, 81171209), the Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Shandong Provincial Outstanding Medical Academic Professional Program, Qingdao Key Health Discipline Development Fund, and Qingdao Outstanding Health Professional Development Fund.
Conflict of Interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wang, ZX., Tan, L., Liu, J. et al. The Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease. Mol Neurobiol 53, 1905–1924 (2016). https://doi.org/10.1007/s12035-015-9143-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-015-9143-0